Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Oct 28;363(18):1734-9.
doi: 10.1056/NEJMoa1007478.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors

Young Lim Choi  1 , Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta, Yuichi Ishikawa, Hideki Kimura, Tetsuya Mitsudomi, Yoshiro Tanio, Hiroyuki Mano; ALK Lung Cancer Study Group
Affiliations
Free article
Case Reports

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors

Young Lim Choi et al. N Engl J Med. .
Free article

Abstract

The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non-small-cell lung cancers, and clinical trials of specific inhibitors of ALK for the treatment of such tumors are currently under way. Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor. Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors. (Funded by the Ministry of Health, Labor, and Welfare of Japan, and others.).

PubMed Disclaimer

Comment in

  • Crizotinib--latest champion in the cancer wars?
    Hallberg B, Palmer RH. Hallberg B, et al. N Engl J Med. 2010 Oct 28;363(18):1760-2. doi: 10.1056/NEJMe1010404. N Engl J Med. 2010. PMID: 20979477 No abstract available.
  • ALK and resistance.
    [No authors listed] [No authors listed] Nat Rev Cancer. 2010 Dec;10(12):817. doi: 10.1038/nrc2976. Nat Rev Cancer. 2010. PMID: 21155181 No abstract available.
  • More on crizotinib.
    Shen L, Ji HF. Shen L, et al. N Engl J Med. 2011 Feb 24;364(8):777-8. doi: 10.1056/NEJMc1013325. N Engl J Med. 2011. PMID: 21345111 No abstract available.

Publication types

MeSH terms

LinkOut - more resources